↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Träfflista för sökning "WFRF:(Knowles D) srt2:(2015-2019)"

Sökning: WFRF:(Knowles D) > (2015-2019)

Resultat 1-10 av 51

Sortera/gruppera träfflistan

Sortering: Träffar per sida:

Numrering	Referens	Omslagsbild	Hitta
1.	Corbalan, R, et al. (författare) Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation: A Report From the GARFIELD-AF Registry 2019 Ingår i: JAMA cardiology. - : American Medical Association (AMA). - 2380-6591 .- 2380-6583. ; 4:6, s. 526-548 Tidskriftsartikel (refereegranskat)
2.	Szarek, M, et al. (författare) Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial 2019 Ingår i: Circulation. Cardiovascular quality and outcomes. - : Ovid Technologies (Wolters Kluwer Health). - 1941-7705 .- 1941-7713. ; 12:11, s. e005858- Tidskriftsartikel (refereegranskat)
3.	Jukema, JW, et al. (författare) Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial 2019 Ingår i: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 74:9, s. 1167-1176 Tidskriftsartikel (refereegranskat)
4.	Ray, KK, et al. (författare) Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial 2019 Ingår i: The lancet. Diabetes & endocrinology. - 2213-8595 .- 2213-8587. ; 7:8, s. 618-628 Tidskriftsartikel (refereegranskat)
5.	Roe, MT, et al. (författare) Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes 2019 Ingår i: Circulation. - : Ovid Technologies (Wolters Kluwer Health). - 1524-4539 .- 0009-7322. ; 140:19, s. 1578-1589 Tidskriftsartikel (refereegranskat)
6.	Szarek, M, et al. (författare) Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial 2019 Ingår i: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 73:4, s. 387-396 Tidskriftsartikel (refereegranskat)
7.	Goodman, SG, et al. (författare) Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery 2019 Ingår i: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 74:9, s. 1177-1186 Tidskriftsartikel (refereegranskat)
8.	Schwartz, GG, et al. (författare) Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome 2018 Ingår i: The New England journal of medicine. - : MASSACHUSETTS MEDICAL SOC. - 1533-4406 .- 0028-4793. ; 379:22, s. 2097-2107 Tidskriftsartikel (refereegranskat)
9.	Davies, G., et al. (författare) Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function 2018 Ingår i: Nature Communications. - : Nature Publishing Group. - 2041-1723. ; 9:1 Tidskriftsartikel (refereegranskat)abstract General cognitive function is a prominent and relatively stable human trait that is associated with many important life outcomes. We combine cognitive and genetic data from the CHARGE and COGENT consortia, and UK Biobank (total N = 300,486; age 16-102) and find 148 genome-wide significant independent loci (P < 5 × 10-8) associated with general cognitive function. Within the novel genetic loci are variants associated with neurodegenerative and neurodevelopmental disorders, physical and psychiatric illnesses, and brain structure. Gene-based analyses find 709 genes associated with general cognitive function. Expression levels across the cortex are associated with general cognitive function. Using polygenic scores, up to 4.3% of variance in general cognitive function is predicted in independent samples. We detect significant genetic overlap between general cognitive function, reaction time, and many health variables including eyesight, hypertension, and longevity. In conclusion we identify novel genetic loci and pathways contributing to the heritability of general cognitive function.
10.	Menden, MP, et al. (författare) Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen 2019 Ingår i: Nature communications. - : Springer Science and Business Media LLC. - 2041-1723. ; 10:1, s. 2674- Tidskriftsartikel (refereegranskat)abstract The effectiveness of most cancer targeted therapies is short-lived. Tumors often develop resistance that might be overcome with drug combinations. However, the number of possible combinations is vast, necessitating data-driven approaches to find optimal patient-specific treatments. Here we report AstraZeneca’s large drug combination dataset, consisting of 11,576 experiments from 910 combinations across 85 molecularly characterized cancer cell lines, and results of a DREAM Challenge to evaluate computational strategies for predicting synergistic drug pairs and biomarkers. 160 teams participated to provide a comprehensive methodological development and benchmarking. Winning methods incorporate prior knowledge of drug-target interactions. Synergy is predicted with an accuracy matching biological replicates for >60% of combinations. However, 20% of drug combinations are poorly predicted by all methods. Genomic rationale for synergy predictions are identified, including ADAM17 inhibitor antagonism when combined with PIK3CB/D inhibition contrasting to synergy when combined with other PI3K-pathway inhibitors in PIK3CA mutant cells.

Skapa referenser, mejla, bekava och länka

Länka till träfflistan

Resultat 1-10 av 51

Avgränsa träffmängd

Typ av publikation: tidskriftsartikel (50); konferensbidrag (1)

Typ av innehåll: refereegranskat (47); övrigt vetenskapligt/konstnärligt (4)

Författare/redaktör: Ripke, S (20); Knowles, JA (20); Gill, M. (20); Sullivan, PF (18); Craddock, N (18); McIntosh, AM (17); visa fler...; Smoller, JW (17); Wray, NR (17); Degenhardt, F (17); Schulze, TG (17); Herms, S. (17); Strohmaier, J (17); Frank, J (17); Witt, SH (17); Breen, G (16); Werge, T (16); Mattheisen, M (16); Cichon, S (16); Montgomery, GW (16); Muller-Myhsok, B (16); Nothen, MM (16); Rietschel, M (16); Martin, NG (16); Kendler, KS (16); O'Donovan, MC (16); Hoffmann, P (15); Medland, SE (15); Levinson, DF (15); Mors, O (15); Esko, T (15); Metspalu, A (15); MacIntyre, DJ (15); Blackwood, DHR (15); Escott-Price, V (15); Steinberg, S (14); Mortensen, PB (14); Webb, BT (14); Lucae, S (14); Lewis, CM (14); Agerbo, E (14); Hougaard, DM (14); Shi, JX (14); Stefansson, K (14); Perlis, RH (14); Treutlein, J (14); Forstner, AJ (14); Stefansson, H. (14); Visscher, PM (14); Bacanu, SA (14); Bigdeli, TB (14); visa färre...

Lärosäte: Karolinska Institutet (44); Uppsala universitet (12); Umeå universitet (10); Göteborgs universitet (7); Lunds universitet (4); Stockholms universitet (3); visa fler...; Kungliga Tekniska Högskolan (2); Linköpings universitet (2); Jönköping University (2); Chalmers tekniska högskola (1); visa färre...

Språk: Engelska (51)

Forskningsämne (UKÄ/SCB): Medicin och hälsovetenskap (29); Naturvetenskap (7); Teknik (1); Samhällsvetenskap (1); Humaniora (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - Nationella bibliotekssystem
LIBRIS.kb.se

pil uppåt

Stäng

Kopiera och spara länken för att återkomma till aktuell vy